KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Boston Scientific (BSX) Non Operating Income (2016 - 2026)

Boston Scientific's Non Operating Income history spans 18 years, with the latest figure at $61.0 million for Q1 2026.

  • On a quarterly basis, Non Operating Income rose 152.59% to $61.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$52.0 million, a 85.98% increase, with the full-year FY2025 number at -$228.0 million, up 28.97% from a year prior.
  • Non Operating Income hit $61.0 million in Q1 2026 for Boston Scientific, up from -$125.0 million in the prior quarter.
  • Over the last five years, Non Operating Income for BSX hit a ceiling of $122.0 million in Q2 2025 and a floor of -$412.0 million in Q4 2022.
  • Historically, Non Operating Income has averaged -$79.6 million across 5 years, with a median of -$83.0 million in 2023.
  • Biggest five-year swings in Non Operating Income: plummeted 575.41% in 2022 and later skyrocketed 222.0% in 2025.
  • Tracing BSX's Non Operating Income over 5 years: stood at -$412.0 million in 2022, then skyrocketed by 80.83% to -$79.0 million in 2023, then dropped by 13.92% to -$90.0 million in 2024, then tumbled by 38.89% to -$125.0 million in 2025, then soared by 148.8% to $61.0 million in 2026.
  • Business Quant data shows Non Operating Income for BSX at $61.0 million in Q1 2026, -$125.0 million in Q4 2025, and -$110.0 million in Q3 2025.